SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 6.26 |
| Enterprise Value ($M) | 1.75 |
| Book Value ($M) | 30.77 |
| Book Value / Share | 4.99 |
| Price / Book | 0.20 |
| NCAV ($M) | -22.41 |
| NCAV / Share | -3.63 |
| Price / NCAV | -0.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.11 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | -0.17 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.81 |
| Current Ratio | 0.98 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 63.05 |
| Assets | 116.23 |
| Liabilities | 85.46 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Stonepine Capital Management, LLC | 9.99 | 10.85 | |
| 13D/A | Nantahala Capital Management, LLC | 18.20 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,524 | 10,175 | 34.63 | |
| 269 | 13,381 | 2.01 | |
| 9,023 | 23,919 | 37.72 | |
| 962 | 19,923 | 4.83 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ATOS – Atossa Therapeutics, Inc. | ATYR – aTyr Pharma, Inc. |
| AVTX – Avalo Therapeutics, Inc. | BCDA – BioCardia, Inc. |
| BCLI – Brainstorm Cell Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io